Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experience

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 639-653

  Overgaard, Marie ^a   Juul Christensen, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER REGISTRY; EARLY CANCER; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HORMONAL THERAPY; HUMAN; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; TREATMENT INDICATION; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; METHODOLOGY; PATHOLOGY; RADIOTHERAPY;

BREAST NEOPLASMS; FEMALE; HUMANS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT;

EID: 45149090756     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802078085     Document Type: Article

References (89)

1. Kaae S, Johansen H. Breast cancer; five year results: Two random series of simple mastectomy with postoperative irradiation versus extended radical mastectomy. Am J Roentgenol Radium Ther Nucl Med 1962;87:82-8.
2. Cuzick J, Stewart H, Peto R, Fisher B, Kaae S, Johansen H, et al. Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treat Rep 1987;71:7-14.
3. Overgaard K. [Result of breast cancer treatment at a central hospital.] Ugeskr Læger. 1961;123:877-9. (in Danish)
4. Johansen H, Kaae S, Jensen M-B, Mouridsen HT. Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study. Acta Oncol 2008;47:633-38.
5. International Commission on Radiation Units and Measurements. ICRU Report 29: Dose specification for reporting external beam therapy with photons and electrons. Bethesda, MD: International Commission on Radiation Units and Measurements; 1978.
6. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
7. Fisher B, Jeong JH, Anderson S, Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96:1823-31.
8. Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group - DBCG: History, organisation, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008;47:491-96.
9. Møller S, Jensen M-B, Ejlertsen B, Bjerre KG, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines programmes of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506-24.
10. Dombernowsky P, Brincker H, Hansen M, Mouridsen HT, Overgaard M, Panduro J, et al. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B. Acta Oncol 1988;27:691-7.
11. Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 1988;27:699-705.
12. Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmussen A, Brincker H, van der Kooy P, et al. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncol 1988;27:707-14.
13. von der Maase H, Sveinsson T. [Combined irradiation and chemotherapy as postoperative treatment of breast cancer] Ugeskr Laeger 1978;140:1676-8. (in Danish)
14. McWhirter R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Brit J Radiol 1948;21:599-610.
15. Ellis F. Dose, time and fractionation: A clinical hypothesis. Clin Radiol 1969;20:1-7.
16. Kirk J, Gray WM, Watson ER. Cumulative radiation effect. I. Fractionated treatment regimes. Clin Radiol 1971;22:145-55.
17. Overgaard M. The clinical implications of non-standard fractionation. Int J Radiat Oncol Biol Phys 1985;11:1225-7.
18. Overgaard M, Bentzen SM, Christensen JJ, Madsen EH. The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiother Oncol 1987;9:1-11.
19. Overgaard M. Spontaneous radiation-induced rib fractures in breast cancer patients treated with postmastectomy irradiation. A clinical radiobiological analysis of the influence of fraction size and dose-response relationships on late bone damage. Acta Oncol 1988;27:117-22.
20. Bentzen SM, Thames HD, Overgaard M. Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiother Oncol 1989;15:267-74.
21. Bentzen SM, Overgaard M, Thames HD. Fractionation sensitivity of a functional endpoint: Impaired shoulder movement after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys 1989;17:531-7.
22. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J, Nielsen OG, Madsen EH. Quantitative assessment of radiation-induced lung changes by computerized optical densitometry of routine chest x-rays. Int J Radiat Oncol Biol Phys 1996;34:421-7.
23. Bentzen SM, Christensen JJ, Overgaard J, Overgaard M. Some methodological problems in estimating radiobiological parameters from clinical data. Alpha/beta ratios and electron RBE for cutaneous reactions in patients treated with postmastectomy radiotherapy. Acta Oncol 1988;27:105-16.
24. Thames HD, Bentzen SM, Turesson I, Overgaard M, van den Bogaert W. Fractionation parameters for human tissues and tumors. Int J Radiat Biol 1989;56:701-10.
25. Bentzen SM, Overgaard M, Thames HD, Christensen JJ, Overgaard J. Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. Int J Radiat Biol 1989;56:711-5.
26. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990;19:219-35.
27. Bentzen SM, Overgaard M. Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol 1991;20:159-65.
28. Bentzen SM, Overgaard M. Early and late normal tissue injury after postmastectomy radiotherapy. Recent Results Cancer Res 1993;130:59-78.
29. Bentzen SM, Overgaard M, Overgaard J. Clinical correlations between late normal tissue endpoints after radiotherapy: Implications for predictive assays of radiosensitivity. Eur J Cancer 1993;29A:1373-6.
30. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88:918-22.
31. Johansen J, Bentzen SM, Overgaard J, Overgaard M. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin ibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Biol 1994;66:407-12.
32. Johansen J, Taagehøj F, Christensen T, Overgaard J, Overgaard M. Quantitative magnetic resonance for assessment of radiation fibrosis after post-mastectomy radiotherapy. Br J Radiol 1994;67:1238-42.
33. Johansen J, Bentzen SM, Overgaard J, Overgaard M. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol 1996;40:101-9.
34. Johansen J, Streffer C, Fuhrmann C, Bentzen SM, Stausbøl- Grøn B, Overgaard M, et al. Radiosensitivity of normal fibroblasts from breast cancer patients assessed by the micronucleus and colony assays. Int J Radiat Biol 1998;73:671-8.
35. Herskind C, Bentzen SM, Overgaard J, Overgaard M, Bamberg M, Rodemann HP. Differentiation state of skin fibroblast cultures versus risk of subcutaneous fibrosis after radiotherapy. Radiother Oncol 1998;47:263-9.
36. Herskind C, Johansen J, Bentzen SM, Overgaard M, Overgaard J, Bamberg M, et al. Fibroblast differentiation in subcutaneous fibrosis after postmastectomy radiotherapy. Acta Oncol 2000;39:383-8.
37. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncol 2005;44:801-15.
38. Andreassen CN, Alsner J, Overgaard M, Sørensen FB, Overgaard J. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM-a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006;82:577-86.
39. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006;64:776-83.
40. Alsner J, Rødningen OK, Overgaard J. Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. Radiother Oncol 2007;83:261-6.
41. Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol 2008;86:314-20.
42. Alsner J, Andreassen CN, Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008;18:126-35.
43. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure: The David A. Karnofsky memorial lecture. Cancer Res 1980;40:3863-74.
44. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1
45. Nielsen HM, Overgaard J, Grau C, Christensen JJ, Overgaard M. Audit of the radiotherapy in the DBCG 82 b&c trials-a validation study of the 1,538 patients randomised to postmastectomy radiotherapy. Radiother Oncol 2005;76:285-92.
46. Højris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 2000;39:355-72.
47. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Loco-regional recurrence after mastectomy in high-risk breast cancer -- risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 2006;79:147-55.
48. Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmussen A, Rose C, van der Kooy P, et al. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990;19:1121-4.
49. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268-75.
50. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
51. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641-8.
52. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247-53.
53. Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol 1999;9:292-9.
54. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 2008;26:1419-26.
55. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, et al. Tissue micro arrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008;47:591-99.
56. Kyndi M, Sørensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, et al. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:608-17.
57. Kyndi M, Sørensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, et al. Prognostic and predictive value of CA IX in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Breast Cancer Res 2008;10:R24.
58. Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Lancet 1999;354:1425-30.
59. Højris I, Sand NP, Andersen J, Rehling M, Overgaard M. Myocardial perfusion imaging in breast cancer patients treated with or without post-mastectomy radiotherapy. Radiother Oncol 2000;55:163-72.
60. Timothy AR, Overgaard J, Overgaard M, Wang CC. Treatment of early carcinoma of the breast. Lancet 1979;2:25-6.
61. Overgaard M, Overgaard J. [Local treatment of cancer of the breast] Ugeskr Læger 1981;143:1401-4. (in Danish)
62. Blichert-Toft M, Brincker H, Andersen JA, Andersen KW, Axelsson CK, Mouridsen HT, et al. A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results. Acta Oncol 1988;27:671-7.
63. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 1992;19-25.
64. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97.
65. Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008;47:672-81.
66. Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M, et al. Cosmetic outcome and breast morbidity in breast-conserving treatment - results from the Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol 2002;41:369-80.
67. Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. Treatment of morbidity associated with the management of the axilla in breast-conserving therapy. Acta Oncol 2000;39:349-54.
68. Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncol 2007;46:525-33.
69. Cuzick J, Stewart H, Peto R, Fisher B, Kaae S, Johansen H, et al. Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treat Rep 1987;71:7-14.
70. Ewertz M, Kempel MM, Düring M, Jensen M-J, Andersson M, Christiansen P, et al. Breast conserving treatment in Denmark, 1989-1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group. Acta Oncol 2008;47:682-90.
71. Overgaard M. Radiotherapy as part of a multidisciplinary treatment strategy in early breast cancer. Eur J Cancer 2001;37(Suppl 7):S33-S43.
72. Nielsen HM, Overgaard M. [Survey of a Cochrane review concerning sequencing of adjuvant chemotherapy and postoperative radiotherapy in breast cancer] Ugeskr Laeger 2007;169:3101-4. (in Danish).
73. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literature. Radiother Oncol 2008;87:3-16.
74. Nielsen HM, Christensen JJ, Aagaard T, Thingholm J, Overgaard M, Grau C. A simple method to test if the internal mammary lymph nodes are covered by the wide tangent technique in radiotherapy for high-risk breast cancer. Clin Oncol 2003;15:17-24.
75. Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998;16:3493-501.
76. Pedersen AN, Korreman S, Nyström H, Specht L. Breathing adapted radiotherapy of breast cancer: Reduction of cardiac and pulmonary doses using voluntary inspiration breathhold. Radiother Oncol 2004;72:53-60.
77. Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 2007;69:1484-95.
78. Thomsen MS, Berg M, Nielsen HM, Pedersen AN, Overgaard M. Ewertz M, et al. Post-mastectomy radiotherapy in Denmark: From 2D to 3D treatment planning guidelines of he Danish Breast Cancer Cooperative Group. Acta Oncol 2008;47:654-61.
79. The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008;9:331-41.
80. The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 2008;371:1098-107.
81. Offersen BV, Overgaard M, Kroman K, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: A systematic review. (submitted).
82. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994;12:2229-34.
83. Bentzen SM. Quantitative clinical radiobiology. DMSc thesis, Faculty of Health, University of Aarhus 1994.
84. Johansen J. Relationship between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of late normal tissue reactions after radiotherapy. Ph.D. thesis, Faculty of Health, University of Aarhus 1995.
85. Jerzy Skoczylas. Clinical studies of the early and late radiation effect in lung tissue. Ph.D. thesis, Faculty of Health, University of Aarhus 1995.
86. Højris I. Late morbidity following systemic treatment with or without postmastectomy irradiation in patients with breast cancer. Ph.D. thesis, Faculty of Health, University of Aarhus 1999.
87. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Ph.D. thesis, Faculty of Health, University of Aarhus 2006.
88. Nielsen HM. Failure pattern following adjuvant systemic therapy with or without postmastectomy radiotherapy in high-risk breast cancer patients. Ph.D. thesis, Faculty of Health, University of Aarhus 2006.
89. Kyndi M. Biological markers predictive of response to adjuvant radiotherapy in breast cancer. Ph.D. thesis, Faculty of Health, University of Aarhus 2008.